This has prompted widespread developmentof STING agonists for cancer immunotherapy, but pharmacological barrierscontinue to limit the clinical impact of STING agonists and motivatethe development of drug delivery systems to improve their efficacyand/or safety. This evidence concerns the gene STING1 and cancer.